文献速递消化系统肿瘤

安罗替尼联合派安普利单抗对比索拉非尼一线治疗不可切除肝细胞癌(APOLLO):一项随机对照3期试验

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-05-08

APOLLO研究为多中心、开放标签、平行对照3期试验,纳入649例不可切除肝细胞癌患者,按2:1随机接受安罗替尼联合派安普利单抗或索拉非尼治疗。联合组中位无进展生存期6.9个月 vs 索拉非尼组2.8个月(HR 0.52,P<0.0001),中位总生存期16.5个月 vs 13.2个月(HR 0.69,P=0.0014)。联合组3级及以上治疗相关不良事件以高血压和血小板计数下降多见。

要点

  • 安罗替尼联合派安普利单抗较索拉非尼显著延长中位无进展生存期(6.9 vs 2.8个月,HR 0.52)。
  • 联合组中位总生存期显著优于索拉非尼组(16.5 vs 13.2个月,HR 0.69)。
  • 联合组3级及以上治疗相关不良事件发生率高于索拉非尼组(高血压17% vs 10%,血小板计数下降9% vs 6%)。

核心结论

  • 安罗替尼联合派安普利单抗较索拉非尼显著改善不可切除肝细胞癌患者的无进展生存期和总生存期,可能成为新的一线选择。
  • 这些发现需要在世界其他地区进行验证。

研究设计与样本

  • APOLLO为多中心、开放标签、平行对照、随机3期试验,在中国79个中心开展。
  • 纳入年龄18-75岁、不可切除肝细胞癌、既往未接受系统治疗、ECOG体能状态0或1的患者。
  • 按2:1随机分配至安罗替尼(10 mg口服每日一次,第1-14天)联合派安普利单抗(200 mg静脉第1天)组或索拉非尼(400 mg口服每日两次)组,每3周重复。
  • 随机化采用中央区组随机化(固定区组大小3),按大血管侵犯或肝外转移、甲胎蛋白浓度、ECOG体能状态分层。
  • 共筛查940例,排除291例,随机分配649例(联合组433例,索拉非尼组216例)。

主要发现

  • 最终无进展生存期分析(2023年6月5日)意向性治疗人群为636例(联合组424例 vs 索拉非尼组212例)。
  • 第二次总生存期中期分析(2024年1月29日)意向性治疗人群为649例(联合组433例 vs 索拉非尼组216例)。
  • 无进展生存期分析中位随访:联合组6.2个月(IQR 5.5-7.5),索拉非尼组4.2个月(IQR 2.9-7.1)。
  • 总生存期分析中位随访:联合组15.3个月(IQR 14.3-17.3),索拉非尼组14.5个月(IQR 11.5-17.0)。
  • 中位无进展生存期:联合组6.9个月(95%CI 5.8-8.0)vs 索拉非尼组2.8个月(95%CI 2.7-4.1),HR 0.52(95%CI 0.41-0.66),P<0.0001。

关键数值与推荐

  • 无进展生存期由盲态独立评审委员会评估,总生存期为意向性治疗人群分析,二者为共同主要终点。
  • 安全性在所有至少接受一剂研究药物且至少有一次安全性评估的参与者中评估。

临床怎么用

  • 安罗替尼联合派安普利单抗可能成为不可切除肝细胞癌的新一线选择,但原文指出需在其他地区验证。

局限性

  • 原文指出这些发现需要在世界其他地区进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy combinations have revolutionised the therapeutic landscape of advanced hepatocellular carcinoma (HCC), but not all yield a significant overall survival benefit, underscoring the need for novel effective agents. Anlotinib plus penpulimab has demonstrated encouraging activity and safety in a phase 2 study. In this phase 3 trial, we aimed to assess whether the combination of anlotinib plus penpulimab improved survival versus sorafenib in patients with unresectable HCC. METHODS: APOLLO was a multicentre, open-label, parallel-controlled, randomised, phase 3 trial conducted at 79 centres in China. Patients aged 18-75 years with unresectable HCC, no previous systemic therapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were randomly assigned (2:1) to anlotinib (10 mg orally once daily on days 1-14) plus penpulimab (200 mg intravenously on day 1), or sorafenib (400 mg orally twice daily) every 3 weeks. Randomisation was done centrally using block randomisation with a fixed block size of 3 and stratified by the presence of macrovascular invasion or extrahepatic metastasis, α-fetoprotein concentration, and ECOG performance status. Sex (male or female) and ethnicity (Chinese or other) were self-reported. The co-primary endpoints were progression-free survival assessed by masked independent review committee and overall survival in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of the study drug and had at least one recorded safety assessment. Final progression-free survival and second interim overall survival analyses are presented. This trial is registered at ClinicalTrials.gov, NCT04344158, and follow-up is ongoing. FINDINGS: From Aug 11, 2020, to June 20, 2023, 940 patients were screened for inclusion in the trial, 291 were excluded, and 649 were randomly assigned to an intervention (433 were assigned to the anlotinib plus penpulimab group and 216 were assigned to the sorafenib group. 551 (85%) of the 649 patients were male and 98 (15%) were female. All patients were Chinese with a median age of 57 years (IQR 50-65). For the final analysis of progression-free survival (June 5, 2023), 636 patients (424 patients in the anlotinib plus penpulimab group vs 212 patients in the sorafenib group) comprised the intention-to-treat population. For the second interim analysis of overall survival (Jan 29, 2024), 649 patients (433 vs 216) comprised the intention-to-treat population. Median follow-up was 6·2 months (IQR 5·5-7·5) for the anlotinib plus penpulimab group and 4·2 months (2·9-7·1) for the sorafenib group for final progression-free survival analysis, and 15·3 months (14·3-17·3) for the anlotinib plus penpulimab group and 14·5 months (11·5-17·0) for the sorafenib group for the second interim overall survival analysis. Median progression-free survival was significantly extended with anlotinib plus penpulimab versus sorafenib (6·9 months [95% CI 5·8-8·0] vs 2·8 months [2·7-4·1]; hazard ratio [HR] 0·52 [95% CI 0·41-0·66]; p<0·0001). Median overall survival was significantly prolonged with anlotinib plus penpulimab compared with sorafenib (16·5 months [95% CI 14·7-19·0] vs 13·2 months [9·7-16·9]; HR 0·69 [95% CI 0·55-0·87]; p=0·0014). The most common grade 3 or worse treatment-related adverse events were hypertension (75 [17%] patients in the anlotinib plus penpulimab group vs 22 [10%] in the sorafenib group) and decrease in platelet count (39 [9%] vs 13 [6%]). Treatment-related serious adverse events occurred in 90 (21%) and 19 (9%) patients in the respective groups; treatment-related deaths occurred in one (<1%) patient in the anlotinib plus penpulimab group (upper gastrointestinal haemorrhage) and two (1%) patients in the sorafenib group (hepatic failure and death of unknown cause). INTERPRETATION: Anlotinib plus penpulimab significantly improved progression-free survival and overall survival versus sorafenib in unresectable HCC and might be a new first-line option. These findings require verification in other regions of the world. FUNDING: Chia Tai Tianqing Pharmaceutical Group.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou J, Bai L, Luo J, et al. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Lancet Oncol. 2025. PMID: 40349716. doi:10.1016/S1470-2045(25)00190-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。